HR 4605 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
End Prescription Drug Ads Now Act
To ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.
Summary
- Bans pharmaceutical manufacturers from conducting direct-to-consumer advertising of prescription drugs.
- Defines direct-to-consumer advertising to include television, radio, print media, digital platforms, and social media marketing targeting consumers.
- Applies to all prescription drugs approved by the FDA or licensed under the Public Health Service Act.
- Takes effect 30 days after enactment and applies retroactively to drugs regardless of when they were previously approved or licensed.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
-
![Rep. Nadler, Jerrold [D-NY-12]](https://media.civicgate.org/people/d/politicians/N000002.thumb.jpg)
Rep. Nadler, Jerrold (D-NY) [#12]
2 cosponsors
-
![Rep. Dexter, Maxine [D-OR-3]](https://media.civicgate.org/people/d/politicians/D000635.thumb.jpg)
Rep. Dexter, Maxine (D-OR) [#3] -
![Rep. Omar, Ilhan [D-MN-5]](https://media.civicgate.org/people/d/politicians/O000173.thumb.jpg)
Rep. Omar, Ilhan (D-MN) [#5]
Money behind the sponsor
Top reported contributors to Jerrold Nadler’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- Employer not reported $14,900
- STANDARD MOTOR PRODUCTS $9,600
- WILMERHALE $7,500
- STV $7,000
- CUNY $6,910
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Jerrold Nadler → · Outside spending →
Actions (2)
- Jul 22, 2025 Referred to the House Committee on Energy and Commerce. · house
- Jul 22, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
July 22, 2025
Mr. Nadler (for himself and Ms. Dexter) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “End Prescription Drug Ads Now Act”.
SEC. 2. PROHIBITION ON DIRECT-TO-CONSUMER DRUG ADVERTISING OF DRUGS.
(a) In General.—Section 502 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following: “(hh)(1) If it is a drug approved under section 505 or licensed under section 351 of the Public Health Service Act, and subject to section 503(b)(1), and the holder of the approved application under section 505 or of the license under such section 351 has conducted direct-to-consumer advertising of the drug within the most recent 30- day period.
“(2) For purposes of this paragraph, the term ‘direct-to-consumer advertising’, with respect to a drug subject to section 503(b)(1), means any promotional communication targeting consumers, including through television, radio, print media, digital platforms, and social media, for purposes of marketing such a drug.”.
(b) Effective Date.—The amendment made by subsection (a) shall take effect 30 days after the date of enactment of this Act, and shall apply with respect to any drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262), regardless of when the drug was approved or licensed. <all>
Comments